States that provide legal access to marijuana through dispensaries experience lower treatment admissions for addiction to pain medication.

Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers?

Published in: Journal of Health Economics Volume 58 (March 2018), Pages 29-42. doi: 10.1016/j.jhealeco.2017.12.007

Posted on RAND.org on February 08, 2018

by David Powell, Rosalie Liccardo Pacula, Mireille Jacobson

Download Support Files

OPTIC-Vetted Medical Marijuana Policy Data

FormatFile SizeNotes
zip file 0.3 MB

The file(s) provided above are ZIP-formatted archives, which most modern systems can natively unpack. If your computer does not unpack the archive when you double-click it, you may need to use a separate decompression program such as UnZip.

Research Question

  1. Do medical marijuana laws reduce addictions and deaths related to pain killers?

Recent work finds that medical marijuana laws reduce the daily doses filled for opioid analgesics among Medicare Part-D and Medicaid enrollees, as well as population-wide opioid overdose deaths. We replicate the result for opioid overdose deaths and explore the potential mechanism. The key feature of a medical marijuana law that facilitates a reduction in overdose death rates is a relatively liberal allowance for dispensaries. As states have become more stringent in their regulation of dispensaries, the protective value generally has fallen. These findings suggest that broader access to medical marijuana facilitates substitution of marijuana for powerful and addictive opioids.

Key Findings

  • The relationship between medical marijuana laws and reductions in opioid overdoses is complex.
  • Medical marijuana laws vary in their effect on reducing opioid overdoses.
  • States with medical marijuana dispensaries experienced reductions in opioid-related overdoses.
  • As states have become more stringent in regulating dispensaries, the protective value of medical marijuana laws generally has fallen.
  • These findings suggest that broader access to medical marijuana facilitates substitution of marijuana for powerful and addictive opioids.
Access further information on this document at Journal of Health Economics Volume 58 (March 2018)

This article was published outside of RAND. The full text of the article can be found at the link above.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.